Compare BCRX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | FTRE |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1994 | N/A |
| Metric | BCRX | FTRE |
|---|---|---|
| Price | $7.20 | $16.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 8 |
| Target Price | ★ $20.08 | $12.07 |
| AVG Volume (30 Days) | ★ 4.0M | 1.4M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $599,816,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $40.20 | $3.17 |
| Revenue Next Year | $7.71 | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.38 | 1.88 |
| 52 Week Low | $6.00 | $3.97 |
| 52 Week High | $11.31 | $20.86 |
| Indicator | BCRX | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 73.87 |
| Support Level | $7.23 | $15.40 |
| Resistance Level | $7.92 | $16.42 |
| Average True Range (ATR) | 0.35 | 1.02 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 13.42 | 81.55 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.